Literature DB >> 12412694

Systemic cytokine levels in community-acquired pneumonia and their association with disease severity.

G Antunes1, S A Evans, J L Lordan, A J Frew.   

Abstract

Pro-inflammatory and anti-inflammatory cytokines are important mediators in the host response to infection. In contrast to the pro-inflammatory cytokines little is known about anti-inflammatory cytokines in community-acquired pneumonia (CAP) and their relation to disease severity. Circulating levels of three pro-inflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumour necrosis factor (TNF)-alpha) and two anti-inflammatory cytokines (IL-10, IL-1 receptor antagonist (IL-1ra)) were measured using an enzyme immunoassay on admission, day 3 and day 5 in 24 patients with CAP. The modified British Thoracic Society (BTS) prognostic rule and Acute Physiology and Chronic Health Evaluation (APACHE) II score were used to assess disease severity. IL-6, TNF-alpha, IL-10 and IL-1ra concentrations were detected in most patients on admission and decreased significantly on day 3 and day 5 in all survivors. A significant difference between the BTS high-risk and low-risk groups was only found for IL-6 (median (range) 477 pg x mL(-1) (7.6-1402 pg x mL(-1)) versus 81.6 pg x mL(-1) (0-943 pg x mL(-1)); p<0.05). IL-6 also correlated with the APACHE II scores on admission. Concentrations of anti-inflammatory cytokines were elevated on admission in community-acquired pneumonia but they did not correlate with disease severity scores.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412694     DOI: 10.1183/09031936.02.00295102

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  59 in total

1.  Dysregulated inflammation as a risk factor for pneumonia in the elderly.

Authors:  Angela R Boyd; Carlos J Orihuela
Journal:  Aging Dis       Date:  2011-12       Impact factor: 6.745

Review 2.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

3.  Effects of volatile vs. propofol-based intravenous anesthetics on the alveolar inflammatory responses to one-lung ventilation: a meta-analysis of randomized controlled trials.

Authors:  Bin Sun; Jinfeng Wang; Lulong Bo; Yan Zang; Haihui Gu; Jinbao Li; Baohua Qian
Journal:  J Anesth       Date:  2015-02-26       Impact factor: 2.078

4.  Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.

Authors:  Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain
Journal:  Clin Infect Dis       Date:  2016-05-10       Impact factor: 9.079

Review 5.  Predictors of treatment failure and clinical stability in patients with community acquired pneumonia.

Authors:  Deirdre Morley; Antoni Torres; Catia Cillóniz; Ignacio Martin-Loeches
Journal:  Ann Transl Med       Date:  2017-11

6.  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.

Authors:  J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez
Journal:  Infection       Date:  2015-09-30       Impact factor: 3.553

7.  Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

Authors:  S Padrones; C Garcia-Vidal; S Fernández-Serrano; A Fernández; C Masuet; J Carratalà; M Coromines; C Ardanuy; F Gudiol; F Manresa; J Dorca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-22       Impact factor: 3.267

8.  Development of a novel preclinical model of pneumococcal pneumonia in nonhuman primates.

Authors:  Bryan D Kraft; Claude A Piantadosi; Ashlee M Benjamin; Joseph E Lucas; Aimee K Zaas; Marisol Betancourt-Quiroz; Christopher W Woods; Alan L Chang; Victor L Roggli; Craig D Marshall; Geoffrey S Ginsburg; Karen Welty-Wolf
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

9.  Severe acute respiratory syndrome: clinical and laboratory manifestations.

Authors:  Christopher W K Lam; Michael H M Chan; Chun K Wong
Journal:  Clin Biochem Rev       Date:  2004-05

10.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.